Novo Nordisk (United Kingdom)

Novo Nordisk UK is the British subsidiary of the Danish pharmaceutical company and global leader in diabetes care, obesity treatment, and rare blood disorders. Key products include Ozempic and Rybelsus (semaglutide) for type 2 diabetes, Wegovy (semaglutide) for chronic weight management, Saxenda (liraglutide) for obesity, Tresiba and Levemir insulins, and NovoSeven for haemophilia.